PLX
insider transactionsProtalix BioTherapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
+55.8K
56.0K buy · 168 sell
Net value · 365d
$101.0K
$101.4K in · $314 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
2
56.0K buy · 168 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Buy·P
Bashan Dror KEY
PRESIDENT AND CEO
$101.4K
56.0K sh · $1.81
Own +42%
-
Sell·S
Director
$314
168 sh · $1.87
Own -100%
-
Grant·A
Director
$0
15.0K sh
Own New
-
Grant·A
Director
—
7.5K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own New
-
Grant·A
Director
—
7.5K sh
Own New
-
Grant·A
Sr. VP, Operations
$0
50.0K sh
Own New
-
Grant·A
Sr. VP, Operations
—
25.0K sh
Own +12%
-
Grant·A
Director
$0
15.0K sh
Own New
-
Grant·A
Director
—
7.5K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own New
-
Grant·A
Director
—
7.5K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own New
-
Grant·A
Director
—
7.5K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own New
-
Grant·A
Director
—
7.5K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own New
-
Grant·A
Director
—
7.5K sh
Own New
-
Grant·A
Bashan Dror KEY
PRESIDENT AND CEO
$0
340.0K sh
Own New
-
Grant·A
Bashan Dror KEY
PRESIDENT AND CEO
—
195.0K sh
Own +9%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Dec 19, 2025 | Bashan Dror KEY | Buy P | 56.0K | $101.4K |
| Nov 18, 2025 | Bar-Shalev Amos | Sell S | 168 | $314 |
| Sep 3, 2025 | Boudes Pol F | Grant A | 15.0K | $0 |
| Sep 3, 2025 | Boudes Pol F | Grant A | 7.5K | — |
| Sep 3, 2025 | Elze Christian | Grant A | 15.0K | $0 |
| Sep 3, 2025 | Elze Christian | Grant A | 7.5K | — |
| Sep 3, 2025 | Naos Yaron | Grant A | 50.0K | $0 |
| Sep 3, 2025 | Naos Yaron | Grant A | 25.0K | — |
| Sep 3, 2025 | Bar-Shalev Amos | Grant A | 15.0K | $0 |
| Sep 3, 2025 | Bar-Shalev Amos | Grant A | 7.5K | — |
| Sep 3, 2025 | Schwartz Aharon | Grant A | 15.0K | $0 |
| Sep 3, 2025 | Schwartz Aharon | Grant A | 7.5K | — |
| Sep 3, 2025 | Melincoff Gwen A | Grant A | 15.0K | $0 |
| Sep 3, 2025 | Melincoff Gwen A | Grant A | 7.5K | — |
| Sep 3, 2025 | Ben Zvi Shmuel | Grant A | 15.0K | $0 |
| Sep 3, 2025 | Ben Zvi Shmuel | Grant A | 7.5K | — |
| Sep 3, 2025 | Forster Eliot | Grant A | 15.0K | $0 |
| Sep 3, 2025 | Forster Eliot | Grant A | 7.5K | — |
| Sep 3, 2025 | Bashan Dror KEY | Grant A | 340.0K | $0 |
| Sep 3, 2025 | Bashan Dror KEY | Grant A | 195.0K | — |
About PLX insider trading
This page tracks insider transactions for Protalix BioTherapeutics, Inc. (PLX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.